4.8 Article

Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells

期刊

CELL
卷 181, 期 6, 页码 1346-+

出版社

CELL PRESS
DOI: 10.1016/j.cell.2020.02.003

关键词

-

资金

  1. Natural Science Foundation of China [81920108028, 81872142]
  2. Guangzhou Science and Technology Program [201904020008]
  3. Key Training Program for Young Scholars of Sun Yat-Sen University [18ykzd07]
  4. Guangdong Science and Technology Department [2017B030314026]
  5. CRUK [C33043/A24478, C8218/A18673]
  6. Worldwide Cancer Research [16-0390, 19-0108]
  7. British Heart Foundation [FS/14/66/31293]
  8. Wellcome Trust Senior Research Fellowship in Clinical Science [103749]
  9. Breast Cancer
  10. NIHR
  11. Barts Charity
  12. BBSRC [BB/L021684/1] Funding Source: UKRI
  13. MRC [G1000089, MR/M019217/1] Funding Source: UKRI

向作者/读者索取更多资源

Enhanced blood vessel (BV) formation is thought to drive tumor growth through elevated nutrient delivery. However, this observation has overlooked potential roles for mural cells in directly affecting tumor growth independent of BV function. Here we provide clinical data correlating high percentages of mural-beta 3-integrin-negative tumor BVs with increased tumor sizes but no effect on BV numbers. Mural-beta 3-integrin loss also enhances tumor growth in implanted and autochthonous mouse tumor models with no detectable effects on BV numbers or function. At a molecular level, mural-cell beta 3-integrin loss enhances signaling via FAK-p-HGFR-p-Akt-p-p65, driving CXCL1, CCL2, and TIMP-1 production. In particular, mural-cell-derived CCL2 stimulates tumor cell MEK1-ERK1/2-ROCK2-dependent signaling and enhances tumor cell survival and tumor growth. Overall, our data indicate that mural cells can control tumor growth via paracrine signals regulated by beta 3-integrin, providing a previously unrecognized mechanism of cancer growth control.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Elucidating the role of the kinase activity of endothelial cell focal adhesion kinase in angiocrine signalling and tumour growth

Emma Newport, Ana Rita Pedrosa, Delphine Lees, Matthew Dukinfield, Edward Carter, Jesus Gomez-Escudero, Pedro Casado, Vinothini Rajeeve, Louise E. Reynolds, Pedro R. Cutillas, Stephen W. Duffy, Beatriz De Luxan Delgado, Kairbaan Hodivala-Dilke

Summary: The study identified the impact of EC FAK kinase activity on tumor cell sensitivity to DNA-damaging therapies, suggesting a modulation of tumor growth and chemotherapy response.

JOURNAL OF PATHOLOGY (2022)

Article Medicine, General & Internal

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Peter W. Horby, Guilherme Pessoa-Amorim, Natalie Staplin, Jonathan R. Emberson, Mark Campbell, Enti Spata, Leon Peto, Nigel J. Brunskill, Simon Tiberi, Victor Chew, Thomas Brown, Hasan Tahir, Beate Ebert, David Chadwick, Tony Whitehouse, Rahuldeb Sarkar, Clive Graham, J. Kenneth Baillie, Buddha Basnyat, Maya H. Buch, Lucy C. Chappell, Jeremy Day, Saul N. Faust, Raph L. Hamers, Thomas Jaki, Edmund Juszczak, Katie Jeffery, Wei Shen Lim, Alan Montgomery, Andrew Mumford, Kathryn Rowan, Guy Thwaites, Marion Mafham, Richard Haynes, Martin J. Landray

Summary: In patients hospitalized with COVID-19, aspirin was not associated with reductions in 28-day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.

LANCET (2022)

Article Oncology

Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity

Marius Tham, Hans-Juergen Stark, Anna Jauch, Catherine Harwood, Elizabeth Pavez Lorie, Petra Boukamp

Summary: The BRAF inhibitor vemurafenib can activate the MEK-ERK signaling pathway in both keratinocytes and fibroblasts, leading to cutaneous adverse events. The effects of vemurafenib on skin keratinocytes depend on their genetic background and can result in tumor progression.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment

Marina Roy-Luzarraga, Louise E. Reynolds, Beatriz de Luxan-Delgado, Oscar Maiques, Laura Wisniewski, Emma Newport, Vinothini Rajeeve, Rebecca J. G. Drake, Jesus Gomez-Escudero, Frances M. Richards, Celine Weller, Christof Dormann, Ya-Ming Meng, Peter B. Vermeulen, Dieter Saur, Victoria Sanz-Moreno, Ping-Pui Wong, Cyrill Geraud, Pedro R. Cutillas, Kairbaan Hodivala-Dilke

Summary: This study reveals that endothelial cell focal adhesion kinase (FAK) plays a role in regulating pancreatic ductal adenocarcinoma (PDAC) metastasis and impacting the outcome of gemcitabine treatment. The findings suggest the potential clinical utility of combinatorial endothelial cell FAK targeting with gemcitabine in controlling metastasis in PDAC patients.

CANCER RESEARCH (2022)

Review Cell Biology

The amoeboid state as part of the epithelial-to-mesenchymal transition programme

Vittoria Graziani, Irene Rodriguez-Hernandez, Oscar Maiques, Victoria Sanz-Moreno

Summary: This review focuses on the role of amoeboid behavior in cancer cell invasion and metastasis, as well as the molecular biomarkers and physicochemical triggers associated with it. The authors suggest that targeting these characteristics could lead to therapeutic opportunities for cancer treatment.

TRENDS IN CELL BIOLOGY (2022)

Article Oncology

M-CSF as a therapeutic target in BRAFV600E melanoma resistant to BRAF inhibitors

C. Barcelo, P. Siso, I. de la Rosa, C. Megino-Luque, R. Navaridas, O. Maiques, I. Urdanibia, N. Eritja, X. Soria, M. Potrony, N. Calbet-Llopart, S. Puig, X. Matias-Guiu, R. M. Marti, A. Macia

Summary: Secreted M-CSF induces a BRAFi-resistant phenotype and signifies a worse prognosis in metastatic BRAF(V600E) melanoma patients. These findings identify secreted M-CSF as a promising therapeutic target for treating BRAFi-resistant melanomas.

BRITISH JOURNAL OF CANCER (2022)

Article Cell Biology

LAP1 supports nuclear adaptability during constrained melanoma cell migration and invasion

Yaiza Jung-Garcia, Oscar Maiques, Joanne Monger, Irene Rodriguez-Hernandez, Bruce Fanshawe, Marie-Charlotte Domart, Matthew J. Renshaw, Rosa M. Marti, Xavier Matias-Guiu, Lucy M. Collinson, Victoria Sanz-Moreno, Jeremy G. Carlton

Summary: Metastasis involves cancer cells spreading from the primary tumor to other sites. Researchers discovered increased expression of the protein LAP1 in metastatic melanoma cells, primary melanoma tumors, and metastases. They found that a shorter isoform of LAP1, LAP1C, supports constrained cell migration and invasion by allowing a weaker coupling between the nuclear envelope and the nuclear lamina. This suggests that LAP1 contributes to melanoma aggressiveness.

NATURE CELL BIOLOGY (2023)

Review Cell Biology

Amoeboid migration in health and disease: Immune responses versus cancer dissemination

Samantha George, Joshua Alexander James Martin, Vittoria Graziani, Victoria Sanz-Moreno

Summary: Cell migration plays a crucial role in immune responses and cancer metastasis. Amoeboid migrating cells use myosin II-powered blebs to move and change their shape and direction. Both immune cells and metastatic cancer cells utilize amoeboid migration, but with different purposes and processes. Exploring the similarities and differences between amoeboid immune and cancer cells can enhance our understanding of metastasis and provide insights for targeted therapies.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)

Article Multidisciplinary Sciences

AMPK is a mechano-metabolic sensor linking cell adhesion and mitochondrial dynamics to Myosin-dependent cell migration

Eva Crosas-Molist, Vittoria Graziani, Oscar Maiques, Pahini Pandya, Joanne Monger, Remi Samain, Samantha L. George, Saba Malik, Jerrine Salise, Valle Morales, Adrien Le Guennec, R. Andrew Atkinson, Rosa M. Marti, Xavier Matias-Guiu, Guillaume Charras, Maria R. Conte, Alberto Elosegui-Artola, Mark Holt, Victoria Sanz-Moreno

Summary: Cell migration is controlled by AMP-activated protein kinase (AMPK) acting as an adhesion sensing molecular hub. High AMPK activity in low adhering migratory cells induces mitochondrial fission and amoeboid migration. Reducing adhesion or activating AMPK promotes efficient rounded-amoeboid migration. This study reveals how mitochondrial dynamics and AMPK contribute to cell migration.

NATURE COMMUNICATIONS (2023)

Article Microbiology

Particular genomic and virulence traits associated with preterm infant-derived toxigenic Clostridium perfringens strains

Raymond Kiu, Alexander G. Shaw, Kathleen Sim, Antia Acuna-Gonzalez, Christopher A. Price, Harley Bedwell, Sally A. Dreger, Wesley J. Fowler, Emma Cornwell, Derek Pickard, Gusztav Belteki, Jennifer Malsom, Sarah Phillips, Gregory R. Young, Zoe Schofield, Cristina Alcon-Giner, Janet E. Berrington, Christopher J. Stewart, Gordon Dougan, Paul Clarke, Gillian Douce, Stephen D. Robinson, J. Simon Kroll, Lindsay J. Hall

Summary: Genomic and phenotypic analyses of 272 infant-associated Clostridium perfringens isolates suggest that pfoA is an important toxin gene in C. perfringens linked with preterm infant intestinal diseases. The gene encoding toxin perfringolysin O, pfoA, was largely deficient in a human-derived hypovirulent lineage, as well as certain colonization factors, in contrast to typical pfoA-encoding virulent lineages. These findings suggest both the importance of pfoA(+)C. perfringens as a gut pathogen in preterm infants and areas for further investigation, including potential intervention and therapeutic strategies.

NATURE MICROBIOLOGY (2023)

Article Microbiology

Allocoprobacillus halotolerans gen. nov., sp. nov and Coprobacter tertius sp. nov., isolated from human gut microbiota

Nancy M. Y. Teng, Raymond Kiu, Rhiannon Evans, David J. Baker, Christian Zenner, Stephen D. Robinson, Lindsay J. Hall

Summary: Two novel bacterial isolates were obtained from faecal samples of patients attending the Breast Care clinic at the Norwich and Norfolk University Hospital. Strain LH1062T was predicted to be a potential novel genus most closely related to Coprobacillus, whilst LH1063T was predicted to be a novel species belonging to Coprobacter. The strains were characterized using various methods, including genetic analysis and phenotypic testing.

INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY (2023)

Article Multidisciplinary Sciences

CD73 controls Myosin II-driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells

Remi Samain, Oscar Maiques, Joanne Monger, Hoyin Lam, Juliana Candido, Samantha George, Nicola Ferrari, Leonie Kohihammer, Sophia Lunetto, Adrian Varela, Jose L. Orgaz, Felip Vilardell, Jorge Juan Olsina, Xavier Matias-Guiu, Debashis Sarker, Adrian Biddle, Frances R. Balkwill, Jim Eyles, Robert W. Wilkinson, Hemant M. Kocher, Fernando Calvo, Claire M. Wells, Victoria Sanz-Moreno

Summary: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to its high metastasis tendency and immunosuppressive microenvironment. The ROCK-Myosin II activity in PDAC cells supports an amoeboid invasive and immunosuppressive program, leading to in vivo metastasis. CD73, an immune checkpoint, is highly expressed in amoeboid PDAC cells and contributes to their invasive, metastatic, and immunomodulatory traits.

SCIENCE ADVANCES (2023)

Review Oncology

Preclinical to clinical utility of ROCK inhibitors in cancer

Jaume Barcelo, Remi Samain, Victoria Sanz-Moreno

Summary: ROCK belongs to the AGC family of Ser/Thr protein kinases and is involved in various cellular processes. It plays a crucial role in regulating cytoskeletal dynamics through actomyosin contractility, which is important for cell migration, proliferation, and survival in many cancer types. Targeting ROCK and its downstream effectors holds potential for cancer treatment, and local use of ROCK inhibitors may reduce side effects. Therefore, different therapeutic strategies and the latest generation of ROCK inhibitors are proposed for clinical use.

TRENDS IN CANCER (2023)

暂无数据